妮子 发表于 2013-8-22 14:06:55

关注，期待新消息

老马 发表于 2013-11-4 15:24:25

Merck says now anticipates odanacatib filing in 2014
Merck reported it recently received and is reviewing safety and efficacy data from the pivotal Phase III trial of odanacatib, the company’s investigational medicine for osteoporosis. As previously indicated, the company has been conducting a blinded extension of the trial in approximately 8,200 women, which will provide additional safety and efficacy data. Merck now anticipates that it will file applications for approval of odanacatib in 2014 with additional data from the extension trial, rather than filing in the first half of 2013. The company continues to believe that odanacatib will have the potential to address unmet medical needs in patients with osteoporosis.

ak780401 发表于 2013-11-4 16:21:14

这个药还没有太多的人用过吧。

东南偏东2013 发表于 2013-11-5 23:34:19

即然福善美能起到治疗骨质疏松症的作用，何必舍近求远吃新药呢。要知道新药的未知数很多呀

ak780401 发表于 2013-11-6 13:19:54

福善美治疗骨质疏松的，针对骨转与择泰比应该弱很多吧，odanacatib是否对骨转也不太强。

风动絮飞 发表于 2013-11-29 20:27:50

有吃过的没有？出来说一下，持续关注中！

煎熬 发表于 2013-12-7 21:46:47

治疗骨痛效果怎么样？

草船借箭 发表于 2013-12-25 21:47:39

论坛里好像没看到有ODN的服药效果统计。

父爱如山-雨儿 发表于 2013-12-27 13:55:40

期待此药！

太阳 发表于 2013-12-31 11:25:17

有个广州的病友用ODN效果不错
页: 1 2 3 4 [5] 6
查看完整版本: 默克的骨转新药：组织蛋白酶K抑制剂Odanacatib